{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:25:16Z","timestamp":1780507516578,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM20\/00205"],"award-info":[{"award-number":["CM20\/00205"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CD23\/00174"],"award-info":[{"award-number":["CD23\/00174"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CIBERINFEC"],"award-info":[{"award-number":["CIBERINFEC"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU 01.702"],"award-info":[{"award-number":["TTU 01.702"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["Ebola-Prep-TBox ID 101145709"],"award-info":[{"award-number":["Ebola-Prep-TBox ID 101145709"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","award":["S2022\/BMD-7274"],"award-info":[{"award-number":["S2022\/BMD-7274"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-44944-0","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:26:36Z","timestamp":1774513596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oral immunization with filovirus-like particles partially protects IFNAR\u2212\/\u2212 mice against lethal ebola virus challenge"],"prefix":"10.1038","volume":"16","author":[{"given":"Beatriz","family":"Escudero-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1tima","family":"Lasala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Luczkowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Labiod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Morgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Nave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Wurr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Garc\u00eda-Bernalt Diego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Mu\u00f1oz-Fontela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"44944_CR1","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1056\/NEJMra1901594","volume":"382","author":"H Feldmann","year":"2020","unstructured":"Feldmann, H., Campion, E. W., Sprecher, A. & Geisbert, T. W. Ebola. N. Engl. J. Med. 382, 1832\u20131842 (2020).","journal-title":"N. Engl. J. Med."},{"key":"44944_CR2","first-page":"363","volume":"315","author":"JP Gonzalez","year":"2007","unstructured":"Gonzalez, J. P., Pourrut, X. & Leroy, E. Ebolavirus and other filoviruses. Curr. Top. Microbiol. Immunol. 315, 363\u2013387 (2007).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"44944_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s00705-023-05834-2","volume":"168","author":"N Biedenkopf","year":"2023","unstructured":"Biedenkopf, N. et al. Renaming of genera Ebolavirus and Marburgvirus to Orthoebolavirus and Orthomarburgvirus, respectively, and introduction of binomial species names within family Filoviridae. Arch. Virol. 168, 220 (2023).","journal-title":"Arch. Virol."},{"key":"44944_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2024.101436","volume":"68\u201369","author":"G Hood","year":"2024","unstructured":"Hood, G. & Carroll, M. Host-pathogen interactions of emerging zoonotic viruses: Bats, humans and filoviruses. Curr. Opin. Virol. 68\u201369, 101436 (2024).","journal-title":"Curr. Opin. Virol."},{"key":"44944_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03901-9","author":"AK Keita","year":"2021","unstructured":"Keita, A. K. et al. Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks. Nature https:\/\/doi.org\/10.1038\/s41586-021-03901-9 (2021).","journal-title":"Nature"},{"key":"44944_CR6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511410","author":"GF Deen","year":"2015","unstructured":"Deen, G. F. et al. Ebola RNA persistence in semen of ebola virus disease survivors: Preliminary report. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa1511410 (2015).","journal-title":"N. Engl. J. Med."},{"key":"44944_CR7","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","volume":"386","author":"AM Henao-Restrepo","year":"2015","unstructured":"Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: Interim results from the Guinea ring vaccination cluster-randomised trial. Lancet Lond. Engl. 386, 857\u2013866 (2015).","journal-title":"Lancet Lond. Engl."},{"key":"44944_CR8","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1056\/NEJMoa1904387","volume":"391","author":"J-J Muyembe","year":"2024","unstructured":"Muyembe, J.-J. et al. Ebola outbreak response in the DRC with rVSV-ZEBOV-GP ring vaccination. N. Engl. J. Med. 391, 2327\u20132336 (2024).","journal-title":"N. Engl. J. Med."},{"key":"44944_CR9","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1001\/jama.2016.4218","volume":"315","author":"ID Milligan","year":"2016","unstructured":"Milligan, I. D. et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: A randomized clinical trial. JAMA 315, 1610\u20131623 (2016).","journal-title":"JAMA"},{"key":"44944_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.coi.2021.03.008","volume":"71","author":"O Tomori","year":"2021","unstructured":"Tomori, O. & Kolawole, M. O. Ebola virus disease: Current vaccine solutions. Curr. Opin. Immunol. 71, 27\u201333 (2021).","journal-title":"Curr. Opin. Immunol."},{"key":"44944_CR11","doi-asserted-by":"publisher","first-page":"246","DOI":"10.4161\/gmic.24197","volume":"4","author":"Q Zhu","year":"2013","unstructured":"Zhu, Q. & Berzofsky, J. A. Oral vaccines: Directed safe passage to the front line of defense. Gut Microbes 4, 246 (2013).","journal-title":"Gut Microbes"},{"key":"44944_CR12","doi-asserted-by":"publisher","first-page":"15889","DOI":"10.1073\/pnas.2237038100","volume":"100","author":"KL Warfield","year":"2003","unstructured":"Warfield, K. L. et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc. Natl. Acad. Sci. U. S. A. 100, 15889\u201315894 (2003).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"44944_CR13","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1016\/j.vaccine.2004.11.070","volume":"23","author":"DL Swenson","year":"2005","unstructured":"Swenson, D. L. et al. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 23, 3033\u20133042 (2005).","journal-title":"Vaccine"},{"key":"44944_CR14","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.5239526","author":"F Lasala","year":"2025","unstructured":"Lasala, F. et al. Oral immunization with filoviral-like particles elicits Ebola virus-specific humoral and cellular immune responses in mice. SSRN Scholarly Pap. https:\/\/doi.org\/10.2139\/ssrn.5239526 (2025).","journal-title":"SSRN Scholarly Pap."},{"key":"44944_CR15","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126070","author":"B Escudero-Perez","year":"2019","unstructured":"Escudero-Perez, B. et al. Comparative pathogenesis of Ebola virus and Reston virus infection in humanized mice. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.126070 (2019).","journal-title":"JCI Insight"},{"key":"44944_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","volume":"169","author":"MA Whitt","year":"2010","unstructured":"Whitt, M. A. Generation of VSV pseudotypes using recombinant \u0394G-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J. Virol. Methods 169, 365\u2013374 (2010).","journal-title":"J. Virol. Methods"},{"key":"44944_CR17","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126070","volume":"4","author":"B Escudero-P\u00e9rez","year":"2019","unstructured":"Escudero-P\u00e9rez, B. et al. Comparative pathogenesis of Ebola virus and Reston virus infection in humanized mice. JCI Insight 4, e126070 (2019).","journal-title":"JCI Insight"},{"key":"44944_CR18","doi-asserted-by":"publisher","first-page":"e615","DOI":"10.1093\/infdis\/jiae613","volume":"231","author":"C Olal","year":"2025","unstructured":"Olal, C. et al. Antibody-based antigen delivery to dendritic cells as a vaccination strategy against Ebola virus disease. J. Infect. Dis. 231, e615\u2013e625 (2025).","journal-title":"J. Infect. Dis."},{"key":"44944_CR19","doi-asserted-by":"publisher","first-page":"S430","DOI":"10.1086\/520583","volume":"196","author":"KL Warfield","year":"2007","unstructured":"Warfield, K. L. et al. Ebola virus\u2010like particle\u2013based vaccine protects nonhuman primates against lethal Ebola virus challenge. J. Infect. Dis. 196, S430\u2013S437 (2007).","journal-title":"J. Infect. Dis."},{"key":"44944_CR20","doi-asserted-by":"publisher","first-page":"24228","DOI":"10.1038\/s41598-024-76163-w","volume":"14","author":"L Vuitika","year":"2024","unstructured":"Vuitika, L. et al. A self-adjuvanted VLPs-based Covid-19 vaccine proven versatile, safe, and highly protective. Sci. Rep. 14, 24228 (2024).","journal-title":"Sci. Rep."},{"key":"44944_CR21","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1099\/0022-1317-82-6-1365","volume":"82","author":"M Bray","year":"2001","unstructured":"Bray, M. The role of the Type I interferon response in the resistance of mice to filovirus infection. J. Gen. Virol. 82, 1365\u20131373 (2001).","journal-title":"J. Gen. Virol."},{"key":"44944_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/v15010158","volume":"15","author":"L Widerspick","year":"2023","unstructured":"Widerspick, L., Steffen, J. F., Tappe, D. & Mu\u00f1oz-Fontela, C. Animal model alternatives in filovirus and bornavirus research. Viruses 15, 158 (2023).","journal-title":"Viruses"},{"key":"44944_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-1-0716-4256-6_15","volume":"2877","author":"E Rodr\u00edguez","year":"2025","unstructured":"Rodr\u00edguez, E., Mu\u00f1oz-Fontela, C. & Escudero-P\u00e9rez, B. Filovirus infection in humanized mouse models. Methods Mol. Biol. (Clifton, N.J.) 2877, 213\u2013226 (2025).","journal-title":"Methods Mol. Biol. (Clifton, N.J.)"},{"key":"44944_CR24","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41591-021-01370-1","volume":"27","author":"BJ Ward","year":"2021","unstructured":"Ward, B. J. et al. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. Nat. Med. 27, 1071\u20131078 (2021).","journal-title":"Nat. Med."},{"key":"44944_CR25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.virol.2018.08.019","volume":"524","author":"K-H Kim","year":"2018","unstructured":"Kim, K.-H. et al. Virus-like particles presenting flagellin exhibit unique adjuvant effects on eliciting T helper type 1 humoral and cellular immune responses to poor immunogenic influenza virus M2e protein vaccine. Virology 524, 172\u2013181 (2018).","journal-title":"Virology"},{"key":"44944_CR26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1089\/vim.2013.0013","volume":"26","author":"F-S Quan","year":"2013","unstructured":"Quan, F.-S. et al. Mucosal adjuvants for influenza virus-like particle vaccine. Viral Immunol. 26, 385\u2013395 (2013).","journal-title":"Viral Immunol."},{"key":"44944_CR27","doi-asserted-by":"publisher","first-page":"5886","DOI":"10.1016\/j.vaccine.2016.10.036","volume":"34","author":"E Poteet","year":"2016","unstructured":"Poteet, E. et al. Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV. Vaccine 34, 5886\u20135894 (2016).","journal-title":"Vaccine"},{"key":"44944_CR28","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01699-24","volume":"98","author":"W Dai","year":"2024","unstructured":"Dai, W. et al. Lipid nanoparticles as adjuvant of norovirus VLP vaccine augment cellular and humoral immune responses in a TLR9- and type I IFN-dependent pathway. J. Virol. 98, e0169924 (2024).","journal-title":"J. Virol."},{"key":"44944_CR29","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.1128\/JVI.75.10.4752-4760.2001","volume":"75","author":"S Gerber","year":"2001","unstructured":"Gerber, S. et al. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J. Virol. 75, 4752\u20134760 (2001).","journal-title":"J. Virol."},{"key":"44944_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1089\/08828240151061365","volume":"14","author":"M Siadat-Pajouh","year":"2001","unstructured":"Siadat-Pajouh, M. & Cai, L. Protective efficacy of rotavirus 2\/6-virus-like particles combined with CT-E29H, a detoxified cholera toxin adjuvant. Viral Immunol. 14, 31\u201347 (2001).","journal-title":"Viral Immunol."},{"key":"44944_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127778","volume":"65","author":"T Hayashi","year":"2025","unstructured":"Hayashi, T. et al. Enhancing vaccine immunogenicity through heterologous prime-boost regimen with multiple nasal boosting with liposomal TLR7 ligand. Vaccine 65, 127778 (2025).","journal-title":"Vaccine"},{"key":"44944_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0593-y","volume":"13","author":"JH Carra","year":"2015","unstructured":"Carra, J. H. et al. A thermostable, chromatographically purified Ebola nano-VLP vaccine. J. Transl. Med. 13, 228 (2015).","journal-title":"J. Transl. Med."},{"key":"44944_CR33","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.1002\/jps.22724","volume":"100","author":"L Hu","year":"2011","unstructured":"Hu, L. et al. Biophysical characterization and conformational stability of Ebola and Marburg virus-like particles. J. Pharm. Sci. 100, 5156\u20135173 (2011).","journal-title":"J. Pharm. Sci."},{"key":"44944_CR34","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01888-22","volume":"97","author":"DM Johnson","year":"2023","unstructured":"Johnson, D. M. et al. Characterization of Ebola Virus mucosal challenge routes in cynomolgus macaques. J. Virol. 97, e0188822 (2023).","journal-title":"J. Virol."},{"key":"44944_CR35","doi-asserted-by":"publisher","first-page":"43339","DOI":"10.1038\/srep43339","volume":"7","author":"PD Walsh","year":"2017","unstructured":"Walsh, P. D. et al. The final (Oral Ebola) vaccine trial on captive chimpanzees?. Sci. Rep. 7, 43339 (2017).","journal-title":"Sci. Rep."},{"key":"44944_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1682418","volume":"16","author":"ZR Stromberg","year":"2026","unstructured":"Stromberg, Z. R. et al. An mRNA vaccine encoding the Ebola virus glycoprotein induces high neutralizing antibody titers and provides strong protection against lethal infections in mouse models. Front. Immunol. 16, 1682418 (2026).","journal-title":"Front. Immunol."},{"key":"44944_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41541-023-00699-7","volume":"8","author":"V Lemmens","year":"2023","unstructured":"Lemmens, V. et al. YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge. Npj Vaccines 8, 99 (2023).","journal-title":"Npj Vaccines"},{"key":"44944_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00615-z","volume":"8","author":"C Yankowski","year":"2023","unstructured":"Yankowski, C., Kurup, D., Wirblich, C. & Schnell, M. J. Effects of adjuvants in a Rabies-vectored Ebola virus vaccine on protection from surrogate challenge. Npj Vaccines 8, 10 (2023).","journal-title":"Npj Vaccines"},{"key":"44944_CR39","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.virol.2013.03.028","volume":"452\u2013453","author":"LM O\u2019Brien","year":"2014","unstructured":"O\u2019Brien, L. M. et al. Vaccination with recombinant adenoviruses expressing Ebola virus glycoprotein elicits protection in the interferon alpha\/beta receptor knock-out mouse. Virology 452\u2013453, 324\u2013333 (2014).","journal-title":"Virology"},{"key":"44944_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.837443","volume":"13","author":"B Bellier","year":"2022","unstructured":"Bellier, B. et al. A thermostable oral SARS-CoV-2 vaccine induces mucosal and protective immunity. Front. Immunol. 13, 837443 (2022).","journal-title":"Front. Immunol."},{"key":"44944_CR41","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00135-23","volume":"97","author":"E Goffin","year":"2023","unstructured":"Goffin, E., Du, X., Hemmi, S., Machiels, B. & Gillet, L. A single oral immunization with a replication-competent adenovirus-vectored vaccine protects mice from Influenza respiratory infection. J. Virol. 97, e0013523 (2023).","journal-title":"J. Virol."},{"key":"44944_CR42","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1172\/JCI81532","volume":"125","author":"M Meyer","year":"2015","unstructured":"Meyer, M. et al. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. J. Clin. Invest. 125, 3241\u20133255 (2015).","journal-title":"J. Clin. Invest."},{"key":"44944_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10030292","volume":"10","author":"T Brasel","year":"2021","unstructured":"Brasel, T. et al. Mucosal challenge ferret models of Ebola Virus Disease. Pathogens 10, 292 (2021).","journal-title":"Pathogens"},{"key":"44944_CR44","doi-asserted-by":"publisher","first-page":"S413","DOI":"10.1086\/520603","volume":"196","author":"A Patel","year":"2007","unstructured":"Patel, A. et al. Mucosal delivery of adenovirus\u2010based vaccine protects against Ebola Virus infection in mice. J. Infect. Dis. 196, S413\u2013S420 (2007).","journal-title":"J. Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44944-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44944-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44944-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:45:19Z","timestamp":1778658319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44944-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["44944"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-44944-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15022"}}